Alnylam Pharmaceuticals, Inc.ALNYNASDAQ
LOADING
|||
EBITDA Over Time
Trending higher, above historical average, slight contraction.
Left:
||||
Earnings before interest, taxes, depreciation, and amortization
Latest
$-178.85M
↑ 68% above average
Average (9y)
$-555.85M
Historical baseline
Range
High:$-178.85M
Low:$-926.56M
CAGR
-4.7%
Modest growth trend
| Period | Value | Change |
|---|---|---|
| 2024 | $-178.85M | +30.7% |
| 2023 | $-258.24M | +72.1% |
| 2022 | $-926.56M | -40.1% |
| 2021 | $-661.56M | +10.2% |
| 2020 | $-736.33M | +15.2% |
| 2019 | $-868.08M | -15.1% |
| 2018 | $-754.24M | -54.5% |
| 2017 | $-488.19M | -19.2% |
| 2016 | $-409.46M | -47.8% |
| 2015 | $-276.96M | - |